FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2736836650> ?p ?o ?g. }

• W2736836650 endingPage "55373" @default.
• W2736836650 startingPage "55361" @default.
• W2736836650 abstract "// Thomas Graillon 1, 2 , David Romano 1 , Céline Defilles 1 , Christophe Lisbonis 1 , Alexandru Saveanu 1, 3 , Dominique Figarella-Branger 5, 6 , Pierre-Hugues Roche 4 , Stéphane Fuentes 2 , Olivier Chinot 6, 7 , Henry Dufour 1, 2 and Anne Barlier 1, 3 1 Aix Marseille Univ, CNRS CRN2M UMR7286, Marseille, France 2 APHM, La Timone Hospital, Department of Neurosurgery, Marseille, France 3 APHM, La Conception Hospital, Molecular Biology Laboratory, Marseille, France 4 APHM, Nord Hospital, Department of Neurosurgery, Marseille, France 5 APHM, La Timone Hospital, Department of Anatomopathology and Neuropathology, Marseille, France 6 Aix Marseille Univ, INSERM, CRO2 UMR911, Marseille, France 7 APHM, La Timone Hospital, Department of Neuro-oncology, Marseille, France Correspondence to: Thomas Graillon, email: tom.graillon@free.fr , Thomas.Graillon@ap-hm.fr Keywords: meningioma, merlin, mTOR, pasireotide, somatostatin Received: February 03, 2017      Accepted: July 12, 2017      Published: July 24, 2017 ABSTRACT Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtype 1 (SST1), SST2, SST3, and SST5 with a high affinity. Pasireotide has a better antisecretory effect in acromegaly, Cushing’s disease, and neuroendocrine tumors than octreotide. In this study, we compared the effects of pasireotide to those of octreotide in vitro on meningioma primary cell cultures, both alone and in combination with the mTOR inhibitor everolimus. Significant mRNA expression levels of SST1, SST2, and SST5 were observed in 40.5%, 100%, and 35% of meningioma samples, respectively. Pasireotide had a significantly stronger inhibitory effect on cell proliferation than octreotide. The effect of pasireotide, but not of octreotide, was significantly stronger in the group expressing the highest level of SST1 mRNA. Combined treatment with pasireotide and everolimus induced a higher reduction in cell viability than that with octreotide plus everolimus. Moreover, pasireotide decreased Akt phosphorylation and reversed everolimus-induced Akt hyperphosphorylation to a higher degree than octreotide. Using 4E-BP1 siRNA (si4E-BP), we demonstrated that 4E-BP1 protein silencing significantly reversed the response to everolimus, both alone and in combination with SSAs. Moreover, si4E-BP completely reversed the inhibition of cyclin D1 expression level and the increase in p27kip1 induced by SSAs, both alone and in combination with everolimus. Our results strongly support the need for further studies on the combination of pasireotide and everolimus in medical therapy for meningiomas." @default.
• W2736836650 created "2017-07-31" @default.
• W2736836650 creator A5000418022 @default.
• W2736836650 creator A5004088077 @default.
• W2736836650 creator A5004223415 @default.
• W2736836650 creator A5006755321 @default.
• W2736836650 creator A5023205638 @default.
• W2736836650 creator A5025206965 @default.
• W2736836650 creator A5032247621 @default.
• W2736836650 creator A5038139940 @default.
• W2736836650 creator A5075387803 @default.
• W2736836650 creator A5078419817 @default.
• W2736836650 creator A5081144362 @default.
• W2736836650 date "2017-07-24" @default.
• W2736836650 modified "2023-10-18" @default.
• W2736836650 title "Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma<i>in vitro</i>" @default.
• W2736836650 cites W1125493649 @default.
• W2736836650 cites W1505110674 @default.
• W2736836650 cites W1757227314 @default.
• W2736836650 cites W1985377196 @default.
• W2736836650 cites W1987132507 @default.
• W2736836650 cites W1996943463 @default.
• W2736836650 cites W1999778073 @default.
• W2736836650 cites W2004519055 @default.
• W2736836650 cites W2012451298 @default.
• W2736836650 cites W2017088119 @default.
• W2736836650 cites W2021165493 @default.
• W2736836650 cites W2027086621 @default.
• W2736836650 cites W2034972449 @default.
• W2736836650 cites W2047999584 @default.
• W2736836650 cites W2057835402 @default.
• W2736836650 cites W2061519720 @default.
• W2736836650 cites W2061761565 @default.
• W2736836650 cites W2068937483 @default.
• W2736836650 cites W2091081767 @default.
• W2736836650 cites W2093854833 @default.
• W2736836650 cites W2099727495 @default.
• W2736836650 cites W2102448688 @default.
• W2736836650 cites W2102554501 @default.
• W2736836650 cites W2103096499 @default.
• W2736836650 cites W2104254929 @default.
• W2736836650 cites W2112064092 @default.
• W2736836650 cites W2117369752 @default.
• W2736836650 cites W2120889045 @default.
• W2736836650 cites W2121425799 @default.
• W2736836650 cites W2123963146 @default.
• W2736836650 cites W2125906767 @default.
• W2736836650 cites W2126765841 @default.
• W2736836650 cites W2128725138 @default.
• W2736836650 cites W2131076971 @default.
• W2736836650 cites W2135503195 @default.
• W2736836650 cites W2138519496 @default.
• W2736836650 cites W2141367928 @default.
• W2736836650 cites W2144027745 @default.
• W2736836650 cites W2156963530 @default.
• W2736836650 cites W2163641526 @default.
• W2736836650 cites W2163856935 @default.
• W2736836650 cites W2172290767 @default.
• W2736836650 cites W2291320440 @default.
• W2736836650 cites W2333540897 @default.
• W2736836650 cites W2343011966 @default.
• W2736836650 cites W2365506339 @default.
• W2736836650 cites W2411574357 @default.
• W2736836650 cites W2433229980 @default.
• W2736836650 cites W2511266187 @default.
• W2736836650 cites W2562974917 @default.
• W2736836650 cites W2708905130 @default.
• W2736836650 cites W392339088 @default.
• W2736836650 doi "https://doi.org/10.18632/oncotarget.19517" @default.
• W2736836650 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5589664" @default.
• W2736836650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28903425" @default.
• W2736836650 hasPublicationYear "2017" @default.
• W2736836650 type Work @default.
• W2736836650 sameAs 2736836650 @default.
• W2736836650 citedByCount "16" @default.
• W2736836650 countsByYear W27368366502018 @default.
• W2736836650 countsByYear W27368366502019 @default.
• W2736836650 countsByYear W27368366502020 @default.
• W2736836650 countsByYear W27368366502021 @default.
• W2736836650 countsByYear W27368366502022 @default.
• W2736836650 countsByYear W27368366502023 @default.
• W2736836650 crossrefType "journal-article" @default.
• W2736836650 hasAuthorship W2736836650A5000418022 @default.
• W2736836650 hasAuthorship W2736836650A5004088077 @default.
• W2736836650 hasAuthorship W2736836650A5004223415 @default.
• W2736836650 hasAuthorship W2736836650A5006755321 @default.
• W2736836650 hasAuthorship W2736836650A5023205638 @default.
• W2736836650 hasAuthorship W2736836650A5025206965 @default.
• W2736836650 hasAuthorship W2736836650A5032247621 @default.
• W2736836650 hasAuthorship W2736836650A5038139940 @default.
• W2736836650 hasAuthorship W2736836650A5075387803 @default.
• W2736836650 hasAuthorship W2736836650A5078419817 @default.
• W2736836650 hasAuthorship W2736836650A5081144362 @default.
• W2736836650 hasBestOaLocation W27368366501 @default.
• W2736836650 hasConcept C126322002 @default.
• W2736836650 hasConcept C143998085 @default.
• W2736836650 hasConcept C2776297358 @default.
• W2736836650 hasConcept C2777433750 @default.

• next